Ohio State Early Investor Network Disclaimer

OSEIN does not provide investment advice, and the information contained in this memo should not be solely relied upon for making investment decisions. Investors are encouraged to conduct their own due diligence and seek professional advice before making any investment. OSEIN does not assume any liability or responsibility for investment outcomes. Additionally, AI was used to review, synthesize, and prepare the following information.

Investing in early-stage and angel investments is inherently risky, and investors should be aware that they may lose their entire investment. By proceeding with any investment, investors acknowledge and assume these risks and understand that the outcomes can be unpredictable and may not result in financial gain.

Company: Coologics

Website: https://coologics.com

Pitch Deck: Coologics Pitch Deck

Make an Investment: Venture360 Deal Page

Key Links

Venture360 Company Profile

Intake and Due Diligence Questionnaire

Draft Coologics Convertible Note

Coologics One Pager

Coologics Enterprise Model (drafted 2023)

Due Diligence Verification: Coologics

Coologics - Post-Pitch Follow Up Q&A

Basic Company Information

  1. Company Name: Coologics
  2. Business Overview: Coologics is a medical device company focused on developing drug-free, cooling-based treatments for vaginal infections and preterm birth prevention. Their flagship product, Vlisse, uses patented technology to provide immediate symptom relief and address the root causes of bacterial vaginosis (BV) and yeast infections, filling a critical gap in women’s health.
  3. Overall Raise: Currently raising $1.5M in a Seed Round, with $800K committed as of early 2025. Plans to raise an additional $1.5M post-clinical trials.
  4. Form of Business Entity: C Corporation